Joshi Alumkal is a physician-scientist. The Alumkal Laboratory’s main emphasis is to understand how genomic and epigenomic changes contribute to lethal prostate cancer progression. They use biochemical, genomic, and epigenomic approaches in cellular models to clarify mechanisms by which key transcriptional regulators function. The most important goals of Alumkal’s studies are to identify therapies that effectively target and interdict lethal prostate cancer progression and to conduct innovative clinical trials designed to validate the molecular and clinical effectiveness of novel therapeutic agents.